Skip to content

Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19

Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04610554
Enrollment
74
Registered
2020-10-30
Start date
2020-05-14
Completion date
2020-10-12
Last updated
2020-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pneumonia

Keywords

COVID-19

Brief summary

Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be associated with diffuse alveolar damage and pulmonary vasculitis. Thus, it is likely that pulmonary function changes may be seen in COVID-19 survivors. The aim of the present study was to test that simultaneously-determined lung diffusing capacity for nitric oxide and carbon monoxide may be useful to detect post-viral diffusive gas exchange abnormalities early after mild-to-severe COVID-19-related pneumonias.

Detailed description

Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be asymptomatic or associated with life-threatening interstitial pneumonia. Clinically, patients affected from severe coronavirus disease-19 (COVID-19) are described as exhibiting rapidly progressing acute respiratory failure with unusually low oxygen levels in arterial blood. On computed tomography scans, diffuse, peripheral ground glass opacities of the lung are seen while autopsy lung specimens showed diffuse alveolar damage and capillary endothelialitis. The objective of the current study, conducted in patients who had recovered from mild-to-severe COVID-19 illness, was to test that simultaneously-determined lung diffusing capacity for nitric oxide (NO) and carbon monoxide (CO) may be of great use to early detect post-infective diffusive gas exchange abnormalities. More specifically, we hypothesized that measurement of membrane diffusive conductance for CO and pulmonary capillary volume may provide accurate information on residual changes of peripheral gas exchanging units of the lung related to previous SARS-CoV-2 infection.

Interventions

None listed

Sponsors

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* subjects were selected after two nasopharyngeal swabs negative for SARS-CoV-2

Exclusion criteria

* severe comorbidities potentially affecting pulmonary gas exchange

Design outcomes

Primary

MeasureTime frameDescription
Lung diffusing capacity for nitric oxide (DLNO)At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2Changes of DLNO after SARS-CoV-2 infection

Secondary

MeasureTime frameDescription
Lung diffusing capacity for carbon monoxide (DLco)At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2Changes of DLco after SARS-CoV-2 infection

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026